source
- Roivant's mosliciguat shows strong efficacy in Phase 2 PH-ILD trialRoivant's experimental drug mosliciguat achieved strong efficacy signals in a Phase 2 study of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The mid-stage trial met its…
- UniQure to release four-year Huntington’s gene therapy results by SeptemberUniQure, a biotech firm, will report four-year data from its Huntington’s disease gene therapy trial before the end of September. The therapy, AMT-130, has already been submitted to regulators in…